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Abstract
Background: Although largely preventable, Australia has one of the highest rates of bowel cancer in the world.
General Practitioners (GPs) have an important role to play in prevention and early detection of bowel cancer,
however in Australia this is yet to be optimised and participation remains low. This study sought to understand
how GPs’ perceptions of bowel screening influence their attitudes to, and promotion of the faecal occult blood test
(FOBT), to identify opportunities to enhance their role.
Methods: Interviews were conducted with 31 GPs from metropolitan and regional New South Wales (NSW),
Australia. Discussions canvassed GPs’ perceptions of their role in bowel screening and the national screening
program; perceptions of screening tests; practices regarding discussing screening with patients; and views on
opportunities to enhance their role. Transcripts were coded using Nvivo and thematically analysed.
Results: The study revealed GPs’ perceptions of screening did not always align with broader public health
definitions of ‘population screening’. While many GPs reportedly understood the purpose of population
screening, notions of the role of asymptomatic screening for bowel cancer prevention were more limited.
Descriptions of screening centred on two major uses: the use of a screening ‘process’ to identify individual
patients at higher risk; and the use of screening ‘tools’, including the FOBT, to aid diagnosis. While the FOBT
was perceived as useful for identifying patients requiring follow up, GPs expressed concerns about its reliability.
Colonoscopy by comparison, was considered by many as the gold standard for both screening and diagnosis.
This perception reflects a conceptualisation of the screening process and associated tools as an individualised
method for risk assessment and diagnosis, rather than a public health strategy for prevention of bowel cancer.
Conclusion: The results show that GPs’ perceptions of screening do not always align with broader public
health definitions of ‘population screening’. Furthermore, the way GPs understood screening was shown to
impact their clinical practice, influencing their preferences for, and use of ‘screening’ tools such as FOBT. The findings
suggest emphasising the preventative opportunity of FOBT screening would be beneficial, as would formally engaging
GPs in the promotion of bowel screening.
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Background
Although largely preventable, Australia has one of the
highest rates of bowel cancer in the world [1]. Early
diagnosis increases the likelihood of successful treat-
ment, however fewer than 40% of bowel cancers are
detected early [2]. A Faecal Occult Blood Test (FOBT)
increases early detection of bowel cancer [3–6], while
detection and removal of pre-cancerous lesions reduces
overall incidence [7]. In Australia, The Clinical Practice
Guidelines for the Prevention, Early Detection and
Management of Colorectal Cancer (2005) recommend
biennial FOBT screening in the average-risk population
[8]. Population screening aims to reduce the burden of
disease in the general population by increasing the likeli-
hood of identifying individuals with the disease before
symptoms develop [9]. It differs significantly from de-
tecting symptomatic cases or ‘individual case finding’ in
asymptomatic patients with certain risk factors [10].
The National Bowel Cancer Screening Program
(NBCSP) commenced in Australia in 2006. The program
uses an immunochemical FOBT and operates by mailing
invitations and FOBT kits directly to eligible individuals’
home addresses based on Medicare data [11]. Currently,
FOBT screening is offered on a 5-yearly basis commen-
cing from age 50, with progression to biennial screening
by 2020 underway [11]. This differs from the bowel
screening program in the United Kingdom, which offers
biennial FOBT screening from age 60 [12], or Japan
which offers annual screening from age 40 . The United
States has no organised program, however screening
with FOBT, sigmoidoscopy or colonoscopy (depending
on individual risk factors) is promoted through guideline
dissemination and media campaigns.
The success of population screening programs de-
pends on high participation, yet suboptimal participation
in bowel screening is common around the world [13]. In
Australia, participation in the NBCSP is around 30%
[11], although it should be noted that some individuals
report screening outside of the NBCSP [14] and are
therefore not captured in this figure. Poor participation
may be attributable to a range of factors including poor
knowledge and awareness [15–17], confusion regarding
recommendations and eligible ages which have changed
over time [15], and lack of General Practitioner (GP) en-
dorsement [17]. There is however, potential to reduce
bowel cancer incidence through a concerted approach to
screening.
In Australia, GPs are the first point of contact that in-
dividuals have with the health system. On average,
Australians visit their GP around five times per year
[18]. At present, GPs have no formal role in recruiting
individuals into the NBCSP however have considerable
potential to encourage participation. GPs play a signifi-
cant role in promoting breast and cervical screening in
line with current recommendations and acknowledge
this as part of their approach to preventative health [19].
In relation to bowel screening, research suggests GP en-
dorsement substantially increases compliance [20–24],
however in Australia there has not yet been a coordi-
nated effort to optimise the role of GPs in promoting
bowel-screening participation.
The importance of screening is gaining attention in
primary care, with national calls for health promotion,
prevention and screening to be recognised as core roles
in general practice [25]. GPs also report feeling positive
towards undertaking prevention and health promotion
activities, however increasing expectations of GPs to
undertake a range of preventative activities in addition
to diagnosing and treating patients should be acknowl-
edged. Discussions about screening can be inhibited by
factors such as time, distractions during consultations,
multiple health concerns, and uncertainty about particu-
lar screening recommendations [26]. Time pressures and
high workload are cited as frequent barriers [19, 27–29].
GPs’ attitudes and level of confidence to initiate health
promotion interventions also influence the inclusion of
such activities in their routine practice [27, 30].
Existing research suggests the success of population-
based screening will largely be determined by GP atti-
tudes and support of the FOBT [31, 32]. It has also been
shown that some GPs have concerns about the efficacy
of the FOBT [33], however it remains unclear as to how
this fits with their understanding of population based
screening and prevention, and to what extent this shapes
their clinical practice. To date we have been unable to
locate any studies that examine specifically how GPs’
perceive population based bowel screening in relation to
cancer prevention, and how this affects their use of the
FOBT. To address this gap, we sought to understand
how GPs’ perceptions of bowel screening influence their
attitudes to, and promotion of the FOBT.
Methods
This study was conducted in 2014, eight years after the
commencement of the NBCSP. A qualitative approach
was selected to enable a nuanced understanding of GPs
perceptions and attitudes. Semi-structured interviews
were conducted with 31 GPs from around NSW who
were recruited through research panels. Research panels
are groups of pre-screened respondents who have
expressed a willingness to participate in research. Pur-
posive sampling was used to ensure representation of
GPs from a variety of metropolitan (n = 16) and regional
(n = 15) locations in NSW. Proportions of males and
females were approximately equal. The sample was
structured to include GPs with a higher proportion of
patients of eligible screening age (50 years and over).
This was done via a screening question asked in the
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recruitment phase that excluded GPs who indicated they
had a relatively low proportion of patients aged over 50.
Interviews were conducted once, either over the
phone or in-person after hours in the clinic, and were
approximately 30 min in duration. Two experienced in-
dependent interviewers from a specialised qualitative
research firm were engaged to conduct the interviews.
All members of the research team, including the ex-
ternal interviewers, were independent of the primary
care sector and no prior relationship existed between
the participants and the researchers/interviewers.
Participants were not informed of the research topic
in advance and were reimbursed for their time. The
interviews followed a discussion guide developed by
the authors (Table 1) and pilot tested by the inter-
viewers. No new themes emerged following the last
few interviews indicating thematic saturation was
reached.
Interviews were transcribed verbatim and coded using
NVivo by the first author, GD. A thematic analysis was
developed around the research objectives and emergent
trends in the data using the approach developed by
Braun and Clarke (2006) [34]. Rigour was addressed
through an iterative process of constant comparison and
the analysis process was documented to ensure process
auditability [35]. A second investigator (JT) reviewed a
random sample of transcripts and analysis to check the
interpretation then the final analysis was developed via a
consultative process involving all authors. Reflexivity
was facilitated through an iterative process of analysis,
with assumptions underpinning interpretations exposed
through comparisons between authors’ interpretations
and with existing evidence. Differences were resolved
through discussion [36]. Participants were not recon-
tacted or provided with copies of the transcripts for veri-
fication, however the authors crosschecked the final
thematic analysis with the interviewers who had con-
ducted a separate independent analysis.
Ethics approval was granted by the University of New
South Wales Human Research Ethics Advisory Panel.
Results
The results are presented in two sections. The first ex-
amines GPs’ perceptions of screening, while the second
section explores their preference for and use of different
screening tools. The range of perspectives and opinions
are illustrated in each section. Overall, GPs acknowl-
edged they had a potentially important role to play in
bowel screening, and support for the NBCSP was wide-
spread despite confusion about its delivery. GPs articu-
lated a range of interpretations of what their role might
entail, including providing education, encouraging com-
pliance, detecting patients who had been missed by the
NBCSP, and facilitating alternative screening pathways.
A few GPs observed that the existence of the NBCSP
meant their role was limited. Although GPs saw their
role in screening to be important, there was variation in
how this translated in their everyday practice, with per-
ceptions of screening observed to exert an important in-
fluence on both attitudes and practice.
Perceptions of ‘screening’
GPs’ perceptions of bowel screening were varied. A few
GPs had a detailed understanding of the meaning of
population screening and the importance of targeting
the asymptomatic population to enable prevention and
early detection of bowel cancer. The majority, however,
referred to screening in terms of identifying risk factors
and facilitating screening for those assessed to be at
higher risk. GPs also referred to screening as part of the
diagnostic process.
The screening ‘process’
Most GPs discussed screening in terms of a diagnostic
or risk assessment ‘process’. GPs spoke about their role
in identifying patients who should be screened due to
pre-existing risk factors. Assessing whether an individual
required screening was seen as the first step in the
‘screening’ process.
In accordance with the National Guidelines [8], age
was a key factor in determining whether screening was a
priority. Other risk factors GPs considered included,
Table 1 Discussion guide
1. What do you see as your role as a GP in cancer screening (general)?
2. What do you see as your role as a GP in bowel screening?
3. What factors influence whether or not you discuss bowel screening
with patients? (Prompt for barriers and enablers)
4. What advice do you give patients regarding bowel screening, and
does this differ depending on the patient? Can you please elaborate?
5. What is your view of different bowel cancer screening tests (FOBT,
colonoscopy, flexible sigmoidoscopy)?
6. From your perspective, how willing are patients to undertake bowel
screening? What factors do you think affect this (patient willingness)?
7. What sources of information about bowel cancer / bowel cancer
screening do you use?
8. What bowel cancer screening guidelines do you know about? What is
available? How useful?
9. What do you know about the NBCSP?
10. What is your opinion of the NBCSP / Understanding of screening
eligibility / The role of GPs in the program?
11. What is your experience of the NBCSP in your practice?
12. When you feel that a patient should have an FOBT, what do you do?
13. What do you do with patients not eligible for the NBCSP?
14. What could help enhance the role of primary care in bowel
screening to improve screening and early detection?
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whether patients had a first-degree family history of
bowel cancer, and the presence or history of gastrointes-
tinal symptoms.
‘My role is basically to find the right kind of patient to
screen, so either age related or [if] they have a strong
family history…’
Male, regional
Screening was also referred to as something that
should be done to address symptoms. This GP was
asked if she had a system for raising screening with pa-
tients. She responded:
‘You ask them if they have any gastrointestinal
symptoms and sure, if there was some suspicion,
then I’d probably put an occult blood on the form’
Female, regional
Some GPs talked about bowel screening specifically in
terms of aiding diagnosis. In these cases ‘screening’ was
used to exclude certain conditions, including cancer, and
hence formed part of the process of diagnosing rather
than screening per se.
‘There are acute triggers, like patients who present
with painful motions, an unexplained change in
bowel habits or new cases of anaemia, that lead me
to recommend FOBT, not so much because I suspect
cancer but more because I want to rule it out as a
possible cause of the patient’s symptoms.’
Male, regional
Screening for early detection and prevention
While the majority of GPs described screening in terms
of an assessment and diagnosis process, a few spoke of
its role in early detection and prevention.
‘I think the studies so far have shown that if we do
screen the population at certain ages, that it does seem
to pick up some of the bowel cancers earlier and
therefore it’s a good thing to do.’
Male, metropolitan
‘Look, we talk about prevention really. It’s good to
practice preventative medicine. So pap smears,
mammograms, for cervical cancer and breast cancer
… and faecal occult blood for bowel cancer.’
Female, metropolitan
The role of population screening and the importance
of targeting the asymptomatic population was also raised
by some GPs.
‘What I see is to pick up cancer in the asymptomatic
population, and the higher the pick-up rate, the better
the outcome because it’s fixable in the early stages, it’s
treatable. So my role is to pick up [cancer] early, as
soon as possible.’
Female, metropolitan
Use of screening tools
GPs perceptions of three types of bowel screening tools
were explored, the colonoscopy, the FOBT and the flex-
ible sigmoidoscopy, although the latter was reported as
being used infrequently. GPs’ attitudes and stated prefer-
ences tended to reflect their conceptualisation of screen-
ing and the perceived utility of specific methods as
diagnostic tools.
For GPs who conceptualised screening in terms of
identifying and assessing patients at higher risk (patients
with a family history or symptoms), then, in accordance
with the National Guidelines [8], colonoscopy was over-
whelmingly the preferred methodology.
‘We have to encourage a vigilant approach, especially
in those with a change in bowel habits or close family
history of bowel cancer, or for patients who have had
polyps removed in the past … These people need
colonoscopy and I refer them to a gastroenterologist to
check for bowel cancer.’
Male, regional
GPs who viewed screening in terms of its diagnostic
end point (detection of cancer) also tended to perceive
colonoscopy was the gold standard ‘screening’ tool as it
enabled a definitive diagnosis to be made.
‘Well, I think at the moment, that [colonscopy’s] the
best way or the gold standard to check for any bowel
disease – bowel polyps and bowel cancer’
Male, metropolitan
‘I mean, a screening test – it has to be valuable and
diagnostic at the same time.’
Female, metropolitan
By the same token, owing to its limitations as a diag-
nostic test, the FOBT was perceived by some to be
inferior.
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‘A faecal occult blood test is a very basic screening tool
which does not necessarily pick up bowel cancer. … I
would only recommend it for the person who is not
agreeable to go for a colonoscopy.’
Female, metropolitan
Several GPs questioned the accuracy of the FOBT, ex-
pressing concerns about the number of false positives.
‘You only need a small amount of blood … and it will
come up positive in your stool, so I usually send them
directly for a colonoscopy.’
Female, regional
Despite both its limitations as a diagnostic tool, and
concerns regarding accuracy, many GPs still saw the
FOBT as a useful tool that could indicate where further
investigation was warranted.
‘It’s a good rough tool. Of course there’s a significant rate
of false positives, and no doubt a rate of false negatives
as well, but it’s not an unreasonable rough tool’
Male, regional
GPs tended to have more positive perceptions of the
FOBT where their concept of screening was population
based. For these GPs, FOBT was recognised as an eco-
nomical, non-invasive tool for identifying individuals re-
quiring further clinical investigation.
‘It seems that there’s really only one screening test:
faecal occult blood testing, FOBT … FOBT is the best
population-screening tool just because it is cheap and
zero-risk to the patient. Of course, it is not a perfect




Increasing FOBT screening as a population measure is
important given its potential to facilitate prevention
and early detection of bowel cancer and reduce overall
disease incidence. GPs have a key role to play in en-
couraging screening participation [20–23], therefore
strategies to formally engage them in the promotion of
routine asymptomatic screening to patients should be
considered [37]. The present study provides important
insight into how GPs both conceptualise screening and
promote use of the FOBT in their clinical practice,
pointing to both opportunities and strategies to en-
hance their role.
This study builds on previous research that has identi-
fied the importance of GPs’ knowledge and attitudes in
shaping their clinical practice in relation to bowel
screening [38, 39] by exploring how these factors impact
on their practice. A novel finding derived from this re-
search shows that GPs’ concepts of screening did not
always align with broader public health definitions of
‘population screening’ [9]. In particular, many GPs did
not appear to have a well-formed understanding of the
role of asymptomatic bowel screening in detecting pre-
cancerous lesions and thus the role of screening in
bowel cancer prevention. GPs frequently construed
screening as either part of a diagnostic process, or re-
served for patients with individualised risk factors or
symptoms. These findings suggest GPs interpret ‘screen-
ing’ within their localised clinical context, rather than
within the broader perspective of population level pre-
vention. Conceptualising screening as either assessing
risk or aiding diagnosis signifies that screening was often
understood as opportunistic detection or individual case
finding. Given clinicians generally operate within the
patient-centric Hippocratic tradition, where how an
intervention helps an individual patient is the most im-
portant determinant, it makes sense that they are less
likely to think in terms of ‘population’ benefits [40]. The
diagnostic emphasis of the medical model amalgamated
with the pressures of time and workload further com-
pound this [29, 38].
Moreover, we found that GPs’ perceptions of screening
influenced both their preferences for, and use of differ-
ent screening tools, with the FOBT often mistakenly
evaluated in terms of its diagnostic capabilities. For GPs
who viewed screening as part of a diagnostic process, it
seems logical that they might prefer a test such as colon-
oscopy, which can more effectively aid diagnosis. Simi-
larly, for GPs who did not make a clear conceptual
distinction between screening and diagnosis, the FOBT
was often mistakenly evaluated in terms of its capabil-
ities as a diagnostic test. As the FOBT is non-specific
and thus limited in its diagnostic capabilities it follows
that colonoscopy would be preferred. Concerns about
false positives (where a cancer diagnosis does not fol-
low), suggests that the FOBT seemed to be widely mis-
understood as to its purpose. Such concerns amongst
GPs have been reported previously by studies under-
taken in the United States [41] and Australia [33]. FOBT
is not a diagnostic test for bowel cancer; rather it is a
test for blood in the stool for which it is very sensitive.
Perceived in those terms, concerns about false positives
should not be widespread. GPs tended to have a more
positive view of the FOBT when it was perceived as a
population-based screening tool to indicate where
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further investigation was required. Having a poor under-
standing of the role of screening in the prevention of
disease is a barrier to the integration of routine asymp-
tomatic bowel screening activities in general practice.
The findings from this study support existing research
that has found the perceived efficacy of screening to be a
determinant of clinical practice [32, 38]. To address
these issues, we need strategies to engage and encourage
GPs to adopt more preventive approaches within their
current models of care. GPs need adequate information
focused around the effectiveness of routine screening
programs, including the proportion of false negatives
and false positives, in order to effectively promote
screening [42]. Targeted information around the natural
history of bowel cancer including pre-cancerous lesions
and the role of asymptomatic screening in prevention
would also provide a useful framework from which to
enhance GPs’ understandings of population screening
[37]. Formally engaging GPs in the promotion of bowel
screening would likely raise the profile of the disease
and reinforce the importance of prevention and early
detection. In France, GPs are directly involved in ad-
ministering the FOBT screening program, which has
been shown to have implications for increased partici-
pation, particularly when the GP delivers the test [38].
The involvement of both GPs and patients in a shared
care approach also provides an opportunity to facilitate
awareness and promote the value of screening [38].
Practice-based strategies that prompt GPs to discuss
screening with eligible patients should also be imple-
mented [43, 44]. This could include establishing systems
that enable GPs to identify patients who are eligible for
screening and trigger a reminder at the time of consult-
ation. Other strategies such as organising special clinics
that focus on preventative activities or involving practice
nurses in screening activities may assist in addressing
some of the practical barriers faced by GPs in promoting
screening to patients [45]. Engaging patients while they
are waiting for a GP visit by asking them to complete a
bowel screening self-assessment, may be another useful
way to initiate discussions about screening and has the
added advantage of fostering a shared decision-making
approach.
Limitations
Although we sought diversity in our sample, it is pos-
sible that this may have been constrained by the recruit-
ment of participants from research panels, which may
limit the applicability of our findings to the broader
population of GPs in NSW. Furthermore, self-report
measures may not always reflect actual practice. Despite
these limitations, the findings highlight important issues,
which if adequately addressed may contribute to increas-
ing bowel screening participation in NSW.
Conclusion
The results of this study show that GPs’ interpretations of
screening do not necessarily align with defined notions of
population screening and the importance of FOBT screen-
ing may therefore be under realised. The findings illustrate
how perceptions of screening influence attitudes and prac-
tice, and suggest a greater emphasis on the preventative
opportunity of FOBT screening would be beneficial, as
would formally engaging GPs in the promotion of bowel
screening. This may assist in re-shaping how some GPs
view the FOBTand utilise it in their clinical practice.
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